Optimizing the Use of Hydroxychloroquine in the Management of COVID-19 Given Its Pharmacological Profile

References (87)

1. 1 Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis [DOI]
2. 2 High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa [DOI]
3. 3 In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) [DOI]
4. 4 Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies [DOI]
5. 5 Chloroquine is a potent inhibitor of SARS coronavirus infection and spread [DOI]
6. 6 The outbreak of COVID-19: An overview [DOI]
7. 7 CLINICAL ORTHOPAEDICS AND RELATED RESEARCH [DOI]
8. 8 Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology [DOI]
9. 9 Effects of chloroquine on viral infections: an old drug against today's diseases [DOI]
10. 10 Clinical progression of patients with COVID-19 in Shanghai, China [DOI]
11. 11 Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS‐CoV‐2 [DOI]
12. 12 The Risk of Toxic Retinopathy in Patients on Long-term Hydroxychloroquine Therapy [DOI]
13. 13 Overview of Therapeutic Drug Monitoring [DOI]
14. 14 Hydroxychloroquine: From Malaria to Autoimmunity [DOI]
15. 15 The SARS-CoV-2 Vaccine Pipeline: an Overview [DOI]
16. 16 Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases [DOI]
17. 17 Coronavirus Cell Entry Occurs through the Endo-/Lysosomal Pathway in a Proteolysis-Dependent Manner [DOI]
18. 18 Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases [DOI]
19. 19 Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model [DOI]
20. 20 Current and Future Use of Chloroquine and Hydroxychloroquine in Infectious, Immune, Neoplastic, and Neurological Diseases: A Mini-Review [DOI]
21. 21 Pharmacokinetic and Pharmacodynamic Changes in the Elderly [DOI]
22. 22 Chronic Hydroxychloroquine Use Associated with QT Prolongation and Refractory Ventricular Arrhythmia [DOI]
23. 23 Hydroxychloroquine attenuates renal ischemia/reperfusion injury by inhibiting cathepsin mediated NLRP3 inflammasome activation [DOI]
24. 24 Hydroxychloroquine Blood Levels in Systemic Lupus Erythematosus: Clarifying Dosing Controversies and Improving Adherence [DOI]
25. 25 The Use of Antimalarial Drugs against Viral Infection [DOI]
26. 26 Hydroxychloroquine decreases Th17-related cytokines in systemic lupus erythematosus and rheumatoid arthritis patients [DOI]
27. 27 Ocular toxicity of hydroxychloroquine.
28. 28 Pharmacology of Chloroquine and Hydroxychloroquine [DOI]
29. 29 COVID-19 R0: Magic Number or Conundrum? [DOI]
30. 30 Different effects of chloroquine and hydroxychloroquine on lysosomal function in cultured retinal pigment epithelial cells [DOI]
31. 31 Dual role of chloroquine in liver ischemia reperfusion injury: reduction of liver damage in early phase, but aggravation in late phase [DOI]
32. 32 CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone [DOI]
33. 33 Safety of hydroxychloroquine in pregnant patients with connective tissue diseases. Review of the literature [DOI]
34. 34 Safety of chloroquine in chemosuppression of malaria during pregnancy. [DOI]
35. 35 Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers. [DOI]
36. 36 Evidence of transplacental passage of hydroxychloroquine in humans [DOI]
37. 37 Drug absorption, distribution, metabolism and excretion considerations in critically ill adults [DOI]
38. 38 Polymeric Nanocarriers for the Delivery of Antimalarials [DOI]
39. 39 Acute Pretreatment with Chloroquine Attenuates Renal I/R Injury in Rats [DOI]
40. 40 Non-Biologic Nanodelivery Therapies for Rheumatoid Arthritis [DOI]
41. 41 Hydroxychloroquine Protects against Cardiac Ischaemia/Reperfusion Injury In Vivo via Enhancement of ERK1/2 Phosphorylation [DOI]
42. 42 The First Pediatric Case of Acute Generalized Exanthematous Pustulosis Caused by Hydroxychloroquine [DOI]
43. 43 Hydroxychloroquine-induced hypoglycaemia in non-diabetic renal patient on peritoneal dialysis [DOI]
44. 44 Pharmacokinetics of codeine and its metabolites in Caucasian healthy volunteers: comparisons between extensive and poor hydroxylators of debrisoquine. [DOI]
45. 45 Chloroquine modulation of specific metabolizing enzymes activities: investigation with selective five drug cocktail [DOI]
46. 46 Hydroxychloroquine in Prophylaxis of Pulmonary Embolism Following Hip Arthroplasty [DOI]
47. 47 Breast milk concentration of hydroxychloroquine in Chinese lactating women with connective tissue diseases [DOI]
48. 48 Hydroxychloroquine: an update [DOI]
49. 49 Early electroretinografic changes in elderly RA patients treated with hydroxychloroquine [DOI]
50. 50 Clinical characteristics of 50466 patients with 2019-nCoV infection [DOI]
51. 51 Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study [DOI]
52. 52 Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1 [DOI]
53. 53 Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial [DOI]
54. 54 Features, Evaluation and Treatment Coronavirus (COVID-19)
55. 55 The pathogenesis and treatment of the `Cytokine Storm' in COVID-19 [DOI]
56. 56 Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19) [DOI]
57. 57 THE JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY [DOI]
58. 58 Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2 [DOI]
59. 59 Chloroquine and hydroxychloroquine as available weapons to fight COVID-19 [DOI]
60. 60 No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection [DOI]
61. 61 Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19) [DOI]
62. 62 COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression [DOI]
63. 63 SARS-CoV-2, SARS-CoV, and MERS-COV: A comparative overview
64. 64 COVID-19: a novel zoonotic disease caused by a coronavirus from China: what we know and what we don’t [DOI]
65. 65 COVID-19 Outbreak: An Overview [DOI]
66. 66 Clinical trials on drug repositioning for COVID-19 treatment [DOI]
67. 67 Insights from nanomedicine into chloroquine efficacy against COVID-19 [DOI]
68. 68 Assessment of the SARS-CoV-2 basic reproduction number, R0, based on the early phase of COVID-19 outbreak in Italy [DOI]
69. 69 Therapeutic management of patients with COVID-19: a systematic review [DOI]
70. 70 Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019 [DOI]
71. 71 Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine [DOI]
72. 72 Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases [DOI]
73. 73 Pathogenesis and treatment of cytokine storm in COVID-19 [DOI]
74. 74 Virological and clinical cure in COVID‐19 patients treated with hydroxychloroquine: A systematic review and meta‐analysis [DOI]
75. 75 Liver and Kidney Injuries in COVID-19 and Their Effects on Drug Therapy; a Letter to Editor. [DOI]
76. 76 Extracorporeal Membrane Oxygenation in the Treatment of Severe Pulmonary and Cardiac Compromise in Coronavirus Disease 2019: Experience with 32 Patients [DOI]
77. 77 Cardiovascular risks of hydroxychloroquine in treatment and prophylaxis of COVID-19 patients: A scientific statement from the Indian Heart Rhythm Society [DOI]
78. 78 The difference in the incubation period of 2019 novel coronavirus (SARS-CoV-2) infection between travelers to Hubei and nontravelers: The need for a longer quarantine period [DOI]
79. 79 Towards Optimization of Hydroxychloroquine Dosing in Intensive Care Unit COVID-19 Patients [DOI]
80. 80 Improving the efficacy of Chloroquine and Hydroxychloroquine against SARS-CoV-2 may require Zinc additives - A better synergy for future COVID-19 clinical trials.
81. 81 Boosting the arsenal against COVID-19 through computational drug repurposing [DOI]
82. 82 Hydroxychloroquine for Treatment of SARS‐CoV‐2 Infection? Improving Our Confidence in a Model‐Based Approach to Dose Selection [DOI]
83. 83 Chloroquine and hydroxychloroquine to treat COVID-19: between hope and caution [DOI]
84. 84 Prospective evaluation of hydroxychloroquine in pediatric interstitial lung diseases: Study protocol for an investigator-initiated, randomized controlled, parallel-group clinical trial [DOI]
85. 85 Findings of Acute Pulmonary Embolism in COVID-19 Patients [DOI]
86. 86 A Large-scale Drug Repositioning Survey for SARS-CoV-2 Antivirals [DOI]
87. 87 Understanding the cell biology of SARS-CoV-2 endocytosis for COVID-19 drug repurposing: looking beyond chloroquine [DOI]

Cited by 21

Showing 12 of 21 known citations — external sources report more than can currently be individually listed.

Related research

• Covid-2019:“A Microbiological Monster” — shares topic coverage
• COVID 19 Disease Caused by Coronavirus 2 (SARS-CoV-2) (Severe Acute Respiratory Syndrome) — shares topic coverage
• Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2): What Can Africa Learn from Ongoing Research in Epidemiology, Clinical Manifestations, Chemotherapy and Prevention? — shares topic coverage
• Azithromycin and Hydroxychloroquine Accelerate Recovery of Outpatients with Mild/Moderate COVID-19 — shares topic coverage
• Early Treatment with Hydroxychloroquine Improves Clinical Outcomes and Reduces Hospital Admissions in COVID-19 Associated Pneumonia — shares topic coverage